Olezarsen is an APOC3-directed antisense oligonucleotide approved for familial chylomicronemia syndrome. This page compares Olezarsen to other lipid-modifying agents such as Plozasiran [Redemplo], Fenofibrate [Tricor], Icosapent ethyl [Vascepa], and Rosuvastatin [Crestor]. A key distinction among these therapies lies in their specific mechanisms of action and approved indications.
Olezarsen Alternatives: How It Compares to Other Triglyceride-Lowering Therapies
Hipa.ai Research · Source: ClinicalTrials.gov / AACT · Last updated: AI-augmented data · 0/7 curated
Source: ClinicalTrials.gov via AACT · Hipa.ai, 2026-05-07Download chart as PNG
The competitive landscape features established treatments such as Fenofibrate (Tricor, 1993) and Rosuvastatin (Crestor, 2003), while Olezarsen was approved in 2024. Several pipeline drugs, including Plozasiran (Redemplo) expected in 2025, and Volanesorsen and Pemafibrate, are currently in Phase 3 development.
Quick comparison table
| Drug | Class | Approved indications | Dosing | Year approved | Lead pivotal endpoint | Annual cost (rough) |
|---|---|---|---|---|---|---|
| Olezarsen (Tryngolza) | APOC3-directed antisense oligonucleotide | Familial chylomicronemia syndrome | 80 mg subcutaneously once monthly | Pipeline | placebo-adjusted mean reduction in fasting triglycerides: 42.5% @ 6 months | $40k |
| Fenofibrate (Tricor) | Fibrate | Severe hypertriglyceridemia, Primary hypercholesterolemia, Mixed dyslipidemia | 48 to 145 mg once daily | 1993 | Triglyceride reduction: -46.2% @ 8 weeks | — |
| Rosuvastatin (Crestor) | HMG-CoA reductase inhibitor | Primary hyperlipidemia, Mixed dyslipidemia, Hypertriglyceridemia, +5 more | 5 to 40 mg once daily | 2003 | — | $100 |
| Icosapent ethyl (Vascepa) | Omega-3 fatty acid | Severe hypertriglyceridemia, Cardiovascular risk reduction | 4 grams daily | 2012 | placebo-adjusted median percentage change in triglycerides: -33.1% @ 12 weeks | $4k |
| Plozasiran (Redemplo) | APOC3-directed siRNA | familial chylomicronemia syndrome | 25 mg subcutaneously once every 3 months | Pipeline | — | $45k |
| Volanesorsen (Waylivra) | Apolipoprotein C-III (ApoC-III) inhibitor | — | 285 mg subcutaneously once weekly for 3 months, then 285 mg every 2 weeks | Pipeline | — | — |
| Pemafibrate (Parmodia) | PPAR-alpha agonist | — | 0.1 mg twice daily | Pipeline | — | — |
Cost estimates are list-price approximations and do not reflect rebates, formulary tier, or out-of-pocket costs after benefits. The class-typical lead-pivotal endpoint here is Triglyceride % change; cells render each drug's actual pivotal endpoint, which may differ. The "Year approved" column shows the FDA approval year for severe hypertriglyceridemia specifically — drugs approved for other indications first appear with their this-indication date, or as Pipeline if not yet approved for this indication. Cross-trial comparisons can mislead — head-to-head Phase-3 data (when present) is below.
Olezarsen vs Plozasiran (Redemplo)
No head-to-head Phase-3 trial directly compares Olezarsen with Plozasiran.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Olezarsen vs Fenofibrate (Tricor)
No head-to-head Phase-3 trial directly compares Olezarsen with Fenofibrate.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Olezarsen vs Icosapent ethyl (Vascepa)
No head-to-head Phase-3 trial directly compares Olezarsen with Icosapent ethyl.
In separate pivotal trials, Olezarsen reported 42.5% placebo-adjusted mean reduction in fasting triglycerides at 6 months (NCT04568434) versus -33.1% placebo-adjusted median percentage change in triglycerides at 12 weeks for Icosapent ethyl (NCT01047683).
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Olezarsen vs Rosuvastatin (Crestor)
No head-to-head Phase-3 trial directly compares Olezarsen with Rosuvastatin.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Pipeline alternatives
Several investigational drugs are currently in active Phase 3 development. Among these is Plozasiran from Arrowhead Pharmaceuticals, which is being evaluated in a lead Phase 3 trial, NCT06347133. Plozasiran is an RNA interference therapeutic designed to reduce angiopoietin-like 3 production, representing a different mechanism of action compared to Olezarsen, which targets apolipoprotein C-III (APOC3). Another investigational agent, Volanesorsen, also targets APOC3, similar to Olezarsen. Pemafibrate, developed by Kowa Research Institute, Inc., is also in Phase 3 development, with a lead trial identified as NCT03001817. Pemafibrate functions as a selective peroxisome proliferator-activated receptor alpha modulator, offering a distinct approach to lipid management.
Choosing between Olezarsen and its alternatives
Olezarsen, an APOC3-directed antisense oligonucleotide, offers a novel mechanistic approach to triglyceride lowering. For patients who may not achieve adequate triglyceride reduction with conventional therapies or where specific modulation of APOC3 is a therapeutic goal, Olezarsen could be considered. Its distinct mechanism targets a key regulator of triglyceride metabolism, potentially providing a new option for managing severe hypertriglyceridemia.
Established therapies provide a range of mechanisms and dosing regimens. Fenofibrate (Tricor), a fibrate, has demonstrated a triglyceride reduction of -46.2% at 8 weeks with daily dosing (48 to 145 mg once daily). Icosapent ethyl (Vascepa), an omega-3 fatty acid, showed a placebo-adjusted median percentage change in triglycerides of -33.1% at 12 weeks, administered as 4 grams daily. Plozasiran (Redemplo), another APOC3-directed therapy utilizing siRNA, offers a subcutaneous dosing schedule of 25 mg once every 3 months, which may appeal for its convenience. Rosuvastatin (Crestor), an HMG-CoA reductase inhibitor, is available in daily doses ranging from 5 to 40 mg. These alternatives, with their diverse mechanisms, established safety profiles, and varying dosing frequencies, may be preferred based on patient comorbidities, concomitant medications, or specific treatment goals.
This information is for educational purposes only and does not constitute medical advice. Clinical decisions regarding patient care should always be made by a qualified prescriber.
Sources and methodology
Trial data was pulled from the ClinicalTrials.gov registry via the AACT relational mirror maintained by the Clinical Trials Transformation Initiative. AACT data freshness: .
Cross-trial comparison limitations:drugs without a direct head-to-head trial are compared using each drug's own pivotal trial. These trials enrolled different patient populations at different time points and used different statistical analysis sets. Cross-trial response-rate differences should not be interpreted as proof that one drug is more effective than another.
Related drug pages on Hipa.ai
Not medical advice. This page summarizes publicly-reported clinical trial data for informational purposes. Treatment decisions belong with a qualified prescribing clinician who knows your medical history. Drug approvals, dosing, and safety profiles change over time — always confirm with the current FDA prescribing information.
olezarsenolezarsen alternativesalternativescomparisonsevere hypertriglyceridemiatriglyceride-lowering-hypertriglyceridemiaolezarsen vs plozasiranolezarsen vs fenofibrateolezarsen vs icosapent ethylolezarsen vs rosuvastatinolezarsen vs volanesorsen